Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) EBITDA (2016 - 2025)

Protalix BioTherapeutics has reported EBITDA over the past 16 years, most recently at $51000.0 for Q4 2025.

  • Quarterly results put EBITDA at $51000.0 for Q4 2025, down 98.87% from a year ago — trailing twelve months through Dec 2025 was -$59000.0 (down 103.18% YoY), and the annual figure for FY2025 was $287000.0, down 86.81%.
  • EBITDA for Q4 2025 was $51000.0 at Protalix BioTherapeutics, down from $2.5 million in the prior quarter.
  • Over the last five years, EBITDA for PLX hit a ceiling of $20.4 million in Q2 2023 and a floor of -$14.3 million in Q4 2023.
  • Median EBITDA over the past 5 years was -$2.3 million (2023), compared with a mean of -$1.5 million.
  • Peak annual rise in EBITDA hit 469.68% in 2023, while the deepest fall reached 472.18% in 2023.
  • Protalix BioTherapeutics' EBITDA stood at -$5.7 million in 2021, then soared by 56.27% to -$2.5 million in 2022, then tumbled by 472.18% to -$14.3 million in 2023, then surged by 131.51% to $4.5 million in 2024, then tumbled by 98.87% to $51000.0 in 2025.
  • The last three reported values for EBITDA were $51000.0 (Q4 2025), $2.5 million (Q3 2025), and $1.5 million (Q2 2025) per Business Quant data.